ALISO VIEJO, Calif., May 24, 2017 -- Cianna Medical, Inc., the world leader in wire-free breast localization, announces that more than 125 medical centers across the U.S. have adopted the Company’s proprietary SCOUT® radar breast localization system. SCOUT is the world’s only radar technology that has application in human tissue, and the system allows surgeons to precisely locate non-palpable breast lesions during a lumpectomy or biopsy surgery with ± 1mm of accuracy. Nationwide, community-based hospitals and leading academic cancer centers including USF Breast Health Program at the University of South Florida, Northwell Health, Houston Methodist Willowbrook Hospital and Houston Methodist The Woodlands Hospital have adopted this groundbreaking technology.
“Our first priority is saving the lives of patients with cancer and, in the process, we strive to improve their radiological and surgical experiences,” said Anne M. Wallace, MD, director of the Comprehensive Breast Health Center at Moores Cancer Center at UC San Diego Health, the 100th hospital to adopt SCOUT. “With wire-free breast localization, there is a dual benefit. The surgeon can perform a more targeted operation that conserves healthy tissue while the patient experiences less discomfort and stress.”
SCOUT is the world’s only non-radioactive, wire-free breast localization system. With SCOUT, the radiologist is able to place a tiny, highly sophisticated reflector at the tumor site with extreme precision. This can be done up to 30 days prior to surgery versus on the same day of surgery which is required with traditional wire localization. Instead of two procedures on the day of surgery, the patient now undergoes one, which can help make the experience significantly less stressful.
During the procedure, the surgeon scans the breast using the SCOUT guide, which emits 50 million pulses per second, allowing the surgeon to “lock” in on the reflector’s precise location with ± 1mm of accuracy. This extraordinary accuracy can help surgeons provide the best possible outcomes. SCOUT has an exceptional detection range of 1mm – 50mm1, documented migration of only <1% across multiple studies1 and is 100% operating room (OR) compatible.
“At Cianna Medical, we have been focused on breast conservation therapy for more than a decade. Our company is dedicated to helping reduce the anxiety and stress breast cancer treatments place on patients and their families. We do this by developing innovative technologies that improve the entire continuum of care,” said Jill Anderson, President and CEO of Cianna Medical. “Reaching adoption at more than 125 centers is a significant milestone and we are grateful for the uncompromising support of our clinical collaborators and dedicated team. We are confident that SCOUT is becoming the new standard of care and will be recognized as the breast localization technology of choice.”
SCOUT was a recent category finalist in the 2016 Fierce Innovation Awards: Life Sciences Edition for outstanding technology innovation in December 2016. SCOUT also received the Scientific Impact Award at the 2016 Society of Breast Surgeons Annual Meeting for data validating its clinical utility. Earlier this year, SCOUT was also honored as a finalist in the 2017 Medical Design Excellence Awards.
For more information, call 866.920.9444 or visit www.ciannamedical.com.
About SCOUT®
The FDA-cleared SCOUT system features a proprietary, highly sophisticated reflector that is precisely placed at the tumor site up to 30 days before a lumpectomy or surgical biopsy. During the procedure, the surgeon scans the breast using the SCOUT guide which emits 50 million pulses per second, allowing the surgeon to “lock” in on the reflector’s precise location with ± 1mm of accuracy. This higher level of localization precision allows better surgical planning that may improve cosmetic results as less tissue may need to be removed. SCOUT has an exceptional detection range of 1mm – 50mm, documented migration of <1% across multiple studies, and is OR compatible.i
About Radar Technology
The SCOUT system uses highly sophisticated radar technology. Radar is used when unprecedented precision is required. Applications using radar include ground penetrating radar, automobile safety systems, flight control systems and antimissile and air-defense systems.
About Cianna Medical, Inc.
Cianna Medical is the world leader in wire-free breast localization and has been focused on breast conservation for over 10 years. Cianna Medical develops, manufactures and markets innovative medical technologies that reduce costs, improve quality and reduce the anxiety and stress breast cancer treatments place on women and their families. Cianna Medical’s world class research, development and commercialization teams developed the world’s first non-radioactive, wire-free breast localization system and the world’s only technology that utilizes radar in tissue. Cianna Medical is focused on expanding applications that continually advance patient care. Its SCOUT and SAVI® Brachy technologies are FDA-cleared and address unmet needs in the delivery of radiation therapy, tumor localization and surgical guidance.
i Cox CE, Russell S, Prowler V, et al. A Prospective, Single Arm, Multi-site, Clinical Evaluation of a Nonradioactive Surgical Guidance Technology for the Location of Nonpalpable Breast Lesions during Excision. Ann Surg Oncol. 2016;23(10):3168-74.
Media Contact: Erich Sandoval LAZAR PARTNERS for Cianna Medical [email protected] 917.497.2867


Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold
Google Disrupts Major Residential Proxy Network IPIDEA
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs
The Maire - EuroChem Case: Three Lessons for Global Business
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 



